Tesofensine
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Tesofensine (TE), an inhibitor of monoamine presynaptic reuptake, has produced twice the weight loss seen with currently marketed…
Background:Tesofensine (TE) is a new drug producing twice the weight loss in obese individuals as seen with currently marketed…
Obesity prevalence has risen dramatically over the past decades, which poses a great number of patients at risk of metabolic and…
Pharmacotherapy of obesity should be an integral part of the comprehensive obesity management program which includes diet…
Tesofensine, a monoamine reuptake inhibitor, is under development by NeuroSearch A/S for the potential treatment of obesity. In…
Results from a phase II trial with Tesofensine for treatment of obesity are presented. In total 203 obese persons were randomised…
Middelen die de eetlust remmen dragen bij tot de behandeling van overgewicht en vetzucht, maar de keuze is beperkt.